RSM01 for Respiratory Syncytial Virus

"This clinical trial is recruiting 56 persons suffering from respiratory syncytial virus between 18 and 49 years of age. To be eligible, they must be in good physical health, have a body mass index (BMI) ranging from 18 to 29.9 kg/m2, as well as agree to remain contactable by the study site across its duration and not relocate during this period. Women must ensure that they are not pregnant or breastfeeding for 28 days prior to their screening date and use contraception whilst taking part in the investigation until 90 days after it concludes; male participants with partners of childbearing potential must follow these same guidelines regarding contraceptives too"

"Our team has assigned RSM01 a score of 1 because this is the initial stage of clinical trials and so far only limited data exists for its safety and efficacy."

"Correct. The clinical trial is actively recruiting, as outlined on the clinicaltrials.gov website. First posted on November 11th 2021, this study seeks 56 participants from a single location and was last edited October 13th 2022."

"This research project has imposed age limits of 18 years and below 49 for inclusion in the study."

"This 151-day trial aims to evaluate the number of systemic adverse events that arise within a 7 day period following medication administration. Secondary goals include determining area under the capillary blood concentration curve over time, tracking safety labs parameters, and measuring peak concentrations in capillary blood on Day 91."

"Clinicaltrials.gov shows that this study is actively recruiting participants. The trial first appeared on November 11th 2021 and its most recent update was October 13th 2022."